Pharmas Jocky for Developing Countries "land grab"

GlaxoSmithKline Plc plans to double revenue from India and China by 2015 as the drugmaker cuts prices to catch up to Pfizer Inc., Sanofi-Aventis SA and Novartis AG in emerging markets.

Glaxo aims to beat the industry's 12 percent to 14 percent growth in developing-country sales, said Abbas Hussain, the president for emerging markets at the London-based company. Worldwide, drug revenue will increase at least 5 percent a year through 2014, according to IMS Health Inc., which tracks pharmaceutical sales.